iO Biosciences
iO BiO Sciences is dedicated to developing innovative cell therapy and biomanufacturing technologies, particularly focusing on off-the-shelf natural killer cell therapies for cancer treatment. Their proprietary GEMS™ technology enables rapid, scalable, and virus-free gene editing and biomanufacturing, facilitating the development of advanced therapeutic products and biologics. The company aims to enhance access to life-saving cancer therapies through its flexible, precise, and efficient platform, with a primary focus on liver cancer and potential for broad oncology applications.
Industries
Nr. of Employees
small (1-50)
iO Biosciences
iO Biosciences, Inc. 3805 Old Easton Road Doylestown, PA 18902
Patents
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
US-12440578-B2
View DetailsNucleic acid constructs comprising gene editing multi-sites and uses thereof
US-10828330-B2
View Details
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
US-12440578-B2
View DetailsNucleic acid constructs comprising gene editing multi-sites and uses thereof
US-10828330-B2
View DetailsProducts
GEMS-modified cell lines (plug-and-play producer or therapeutic cell clones)
Modified cell clones created by directed, virus-free gene editing that serve as reusable plug-and-play producer lines for protein/viral vector manufacture or as universal therapeutic cell sources for CAR expression.
Off-the-shelf NK cell therapy candidates (preclinical)
Stem cell-derived, allogeneic NK cell therapy candidates engineered to express CARs with an initial development focus on liver cancer and additional in-licensed pan-cancer programs.
GEMS-modified cell lines (plug-and-play producer or therapeutic cell clones)
Modified cell clones created by directed, virus-free gene editing that serve as reusable plug-and-play producer lines for protein/viral vector manufacture or as universal therapeutic cell sources for CAR expression.
Off-the-shelf NK cell therapy candidates (preclinical)
Stem cell-derived, allogeneic NK cell therapy candidates engineered to express CARs with an initial development focus on liver cancer and additional in-licensed pan-cancer programs.
Services
Out-license gene-editing platform and perform conversion of customer therapeutic or manufacturing cell lines into plug-and-play systems; deliver modified clones or transfer to CDMO for expansion.
Out-license gene-editing platform and perform conversion of customer therapeutic or manufacturing cell lines into plug-and-play systems; deliver modified clones or transfer to CDMO for expansion.
Expertise Areas
- Allogeneic cell therapy development
- Stem cell engineering and differentiation
- CAR (chimeric antigen receptor) engineering
- Gene editing and genome engineering
Key Technologies
- CRISPR and alternative gene-editing methods
- Electroporation-based transfection
- Stem cell-derived NK cell differentiation
- CHO cell engineering for biologics production